Changing the world
UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.
Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies
– A CD19 CAR with novel targeting properties designed to reduce cytokine release syndrome –
Autolus Limited, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the execution of a license agreement under which Autolus has acquired global rights from UCL Business plc (UCLB), the technology-transfer company of University College London (UCL), to develop and commercialize a novel CD19 chimeric antigen receptor (CAR) T cell therapy with novel targeting properties for the treatment of B cell malignancies.
Novel method of analysis of stroke data
Latest news and highlights
Bringing innovation to life